Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2004-2012

ABSTRACT

This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation for collection for transplantation. Although a sufficient quantity of cells usually can be collected with G-CSF treatment, some donors do not respond well and may require multiple apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem cells for collection than G-CSF alone. The Food and Drug Administration has approved G-CSF for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers within a few hours. Normal healthy volunteers between 18 and 60 years of age may be eligible for this study. Detailed Description Peripheral blood progenitor cells (PBPC) are the most popular source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and faster engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% of the donors will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. AMD3100 reversibly inhibits CXC- chemokine receptor 4 (CXCR4) binding to stromal cell derived factor (SDF) - 1 and was recently discovered to be an effective agent to mobilize cluster of differentiation 34 (CD34)+ cells into the peripheral blood. In normal volunteers, administering AMD3100 after 4-5 days of G-CSF resulted in a 3-3.5 fold increase in circulating CD34 cells compared to G-CSF alone. Recent data has suggested that the combination of G-CSF and AMD3100 is superior to G-CSF alone for mobilizing hematopoietic progenitor cells in heavily pretreated patients with multiple myeloma or non-Hodgkin's lymphoma undergoing autologous hematopoietic transplantation. Combining AMD3100 with G-CSF could be an effective strategy to improve the yield of PBPC collected from allogeneic donors who mobilize poorly with G-CSF alone. However, the biological impact of AMD3100 in this context on T cells and other cellular populations contained within the allograft that mediate graft versus host disease (GVHD) and graft-versus-leukemia (GVL) effects are unknown. We propose to collect peripheral progenitor cell (PBPC) from healthy volunteers following 5 days of G-CSF (10 mcg/kg/day) and a single dose of AMD3100 (240 mcg/kg subcutaneous given 12 hours before starting apheresis) to study the impact of combining these two mobilizing agents on the immunological properties of the mobilized cells. A single 15 liter apheresis will be conducted on day 5 following the 5th dose of G-CSF. The immunological studies conducted on these mobilized cells will be the same as our parallel study which is investigating the immune properties of PBPCs mobilized with G-CSF or AMD3100 alone. If combining AMD3100 with G-CSF has no negative impact on the immune populations involved in GVHD and graft-vs-leukemia effects, this regimen could be used for allogeneic donors who fail to mobilize sufficient peripheral blood stem cell (PBSC) using G-CSF alone. Primary objective: To determine the cytokine polarization status of cluster of differentiation 4 (CD4+) T-cells collected by apheresis following combination of AMD3100 and G-CSF compared to G-CSF mobilization. Primary endpoint: the ratio of Th1 [intracellular interferon (IFN-g) +] versus Th2 [intracellular interleukin (IL-4+)] T-cells in the apheresis products collected from individual donors undergoing mobilization with combination of G-CSF and AMD3100 to the ratio in apheresis product collected with G-CSF alone (ratio published in literature). Secondary endpoints: To examine 1) the cellular content and other immune properties of mobilized cells; 2) yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis; and the 3) safety profile of AMD3100. More... »

URL

https://clinicaltrials.gov/show/NCT00082329

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation for collection for transplantation. Although a sufficient quantity of cells usually can be collected with G-CSF treatment, some donors do not respond well and may require multiple apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem cells for collection than G-CSF alone. The Food and Drug Administration has approved G-CSF for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers within a few hours. Normal healthy volunteers between 18 and 60 years of age may be eligible for this study.\n\nDetailed Description\nPeripheral blood progenitor cells (PBPC) are the most popular source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and faster engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% of the donors will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. AMD3100 reversibly inhibits CXC- chemokine receptor 4 (CXCR4) binding to stromal cell derived factor (SDF) - 1 and was recently discovered to be an effective agent to mobilize cluster of differentiation 34 (CD34)+ cells into the peripheral blood. In normal volunteers, administering AMD3100 after 4-5 days of G-CSF resulted in a 3-3.5 fold increase in circulating CD34 cells compared to G-CSF alone. Recent data has suggested that the combination of G-CSF and AMD3100 is superior to G-CSF alone for mobilizing hematopoietic progenitor cells in heavily pretreated patients with multiple myeloma or non-Hodgkin's lymphoma undergoing autologous hematopoietic transplantation. Combining AMD3100 with G-CSF could be an effective strategy to improve the yield of PBPC collected from allogeneic donors who mobilize poorly with G-CSF alone. However, the biological impact of AMD3100 in this context on T cells and other cellular populations contained within the allograft that mediate graft versus host disease (GVHD) and graft-versus-leukemia (GVL) effects are unknown. We propose to collect peripheral progenitor cell (PBPC) from healthy volunteers following 5 days of G-CSF (10 mcg/kg/day) and a single dose of AMD3100 (240 mcg/kg subcutaneous given 12 hours before starting apheresis) to study the impact of combining these two mobilizing agents on the immunological properties of the mobilized cells. A single 15 liter apheresis will be conducted on day 5 following the 5th dose of G-CSF. The immunological studies conducted on these mobilized cells will be the same as our parallel study which is investigating the immune properties of PBPCs mobilized with G-CSF or AMD3100 alone. If combining AMD3100 with G-CSF has no negative impact on the immune populations involved in GVHD and graft-vs-leukemia effects, this regimen could be used for allogeneic donors who fail to mobilize sufficient peripheral blood stem cell (PBSC) using G-CSF alone. Primary objective: To determine the cytokine polarization status of cluster of differentiation 4 (CD4+) T-cells collected by apheresis following combination of AMD3100 and G-CSF compared to G-CSF mobilization. Primary endpoint: the ratio of Th1 [intracellular interferon (IFN-g) +] versus Th2 [intracellular interleukin (IL-4+)] T-cells in the apheresis products collected from individual donors undergoing mobilization with combination of G-CSF and AMD3100 to the ratio in apheresis product collected with G-CSF alone (ratio published in literature). Secondary endpoints: To examine 1) the cellular content and other immune properties of mobilized cells; 2) yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis; and the 3) safety profile of AMD3100.", 
    "endDate": "2012-10-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00082329", 
    "keywords": [
      "peripheral blood", 
      "Granulocyte Colony-Stimulating Factor", 
      "AMD3100", 
      "plerixafor", 
      "healthy volunteer", 
      "stem cell", 
      "collection", 
      "growth factor", 
      "bone marrow", 
      "blood circulation", 
      "transplantation", 
      "sufficient quantity", 
      "cell", 
      "CSF", 
      "Tissue Donor", 
      "United State Food and Drug Administration", 
      "Hematopoietic Stem Cell Mobilization", 
      "drug", 
      "large number", 
      "age", 
      "peripheral blood progenitor cell", 
      "hematopoetic stem cell", 
      "Homologous Transplantation", 
      "ease", 
      "engraftment", 
      "procure", 
      "peripheral blood stem cell", 
      "regimen", 
      "adequate number", 
      "healthy donor", 
      "large volume", 
      "chemokine receptor", 
      "binding", 
      "stromal cell", 
      "effective agent", 
      "cluster", 
      "CD34", 
      "fold increase", 
      "recent data", 
      "hematopoietic stem cell", 
      "patient", 
      "multiple myeloma", 
      "lymphoma", 
      "combining", 
      "effective strategy", 
      "biological impact", 
      "T cell", 
      "cellular population", 
      "allograft", 
      "graft host disease", 
      "Graft vs Host Disease", 
      "graft-versus-leukemia", 
      "progenitor", 
      "single dose", 
      "mcg/kg", 
      "Blood Component Removal", 
      "agent", 
      "immunological property", 
      "dose", 
      "immunological study", 
      "parallel study", 
      "negative impact", 
      "population", 
      "leukemia", 
      "primary objective", 
      "polarization", 
      "T lymphocyte", 
      "mobilization", 
      "primary endpoint", 
      "ratio", 
      "Th1", 
      "interferon", 
      "IFN-g", 
      "Th2", 
      "interleukin", 
      "IL", 
      "product", 
      "individual", 
      "secondary endpoint", 
      "cellular content", 
      "immune cell", 
      "cellular subset", 
      "safety profile"
    ], 
    "name": "Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00082329"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00001.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.279885.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2004-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/sj.bmt.1702464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035763692", 
          "https://doi.org/10.1038/sj.bmt.1702464"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1701522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046074771", 
          "https://doi.org/10.1038/sj.bmt.1701522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082852193", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00082329"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00082329'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00082329'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00082329'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00082329'


 

This table displays all metadata directly associated to this object as RDF triples.

117 TRIPLES      16 PREDICATES      103 URIs      92 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00082329 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 schema:description This 12-day study will test whether the combination of G-CSF (granulocyte-colony stimulating factor) and AMD3100 (Mozobil) is more efficient in mobilizing stem cells for collection than the use of G-CSF alone. Traditionally, the growth factor G-CSF has been given to stem cell donors to mobilize, or push, stem cells out of the bone marrow and into the blood circulation for collection for transplantation. Although a sufficient quantity of cells usually can be collected with G-CSF treatment, some donors do not respond well and may require multiple apheresis procedures (see below) to collect enough cells. Studies indicate that G-CSF used together with a drug called AMD3100 may be more effective in mobilizing stem cells for collection than G-CSF alone. The Food and Drug Administration has approved G-CSF for stem cell mobilization. AMD3100 is a new drug that also mobilizes stem cells in large numbers within a few hours. Normal healthy volunteers between 18 and 60 years of age may be eligible for this study. Detailed Description Peripheral blood progenitor cells (PBPC) are the most popular source of hematopoetic stem cells for allogeneic transplantation because of technical ease of collection and faster engraftment. Traditionally, granulocyte-colony stimulating factor (G-CSF) has been used to procure the peripheral blood stem cell graft. Although regimens using G-CSF usually succeed in collecting adequate numbers of PBPC from healthy donors, 5%-10% of the donors will mobilize stem cells poorly and may require multiple large volume apheresis or bone marrow harvesting. AMD3100 reversibly inhibits CXC- chemokine receptor 4 (CXCR4) binding to stromal cell derived factor (SDF) - 1 and was recently discovered to be an effective agent to mobilize cluster of differentiation 34 (CD34)+ cells into the peripheral blood. In normal volunteers, administering AMD3100 after 4-5 days of G-CSF resulted in a 3-3.5 fold increase in circulating CD34 cells compared to G-CSF alone. Recent data has suggested that the combination of G-CSF and AMD3100 is superior to G-CSF alone for mobilizing hematopoietic progenitor cells in heavily pretreated patients with multiple myeloma or non-Hodgkin's lymphoma undergoing autologous hematopoietic transplantation. Combining AMD3100 with G-CSF could be an effective strategy to improve the yield of PBPC collected from allogeneic donors who mobilize poorly with G-CSF alone. However, the biological impact of AMD3100 in this context on T cells and other cellular populations contained within the allograft that mediate graft versus host disease (GVHD) and graft-versus-leukemia (GVL) effects are unknown. We propose to collect peripheral progenitor cell (PBPC) from healthy volunteers following 5 days of G-CSF (10 mcg/kg/day) and a single dose of AMD3100 (240 mcg/kg subcutaneous given 12 hours before starting apheresis) to study the impact of combining these two mobilizing agents on the immunological properties of the mobilized cells. A single 15 liter apheresis will be conducted on day 5 following the 5th dose of G-CSF. The immunological studies conducted on these mobilized cells will be the same as our parallel study which is investigating the immune properties of PBPCs mobilized with G-CSF or AMD3100 alone. If combining AMD3100 with G-CSF has no negative impact on the immune populations involved in GVHD and graft-vs-leukemia effects, this regimen could be used for allogeneic donors who fail to mobilize sufficient peripheral blood stem cell (PBSC) using G-CSF alone. Primary objective: To determine the cytokine polarization status of cluster of differentiation 4 (CD4+) T-cells collected by apheresis following combination of AMD3100 and G-CSF compared to G-CSF mobilization. Primary endpoint: the ratio of Th1 [intracellular interferon (IFN-g) +] versus Th2 [intracellular interleukin (IL-4+)] T-cells in the apheresis products collected from individual donors undergoing mobilization with combination of G-CSF and AMD3100 to the ratio in apheresis product collected with G-CSF alone (ratio published in literature). Secondary endpoints: To examine 1) the cellular content and other immune properties of mobilized cells; 2) yields of hematopoietic progenitor cells, immune cells, and other cellular subsets collected by apheresis; and the 3) safety profile of AMD3100.
4 schema:endDate 2012-10-01T00:00:00Z
5 schema:keywords AMD3100
6 Blood Component Removal
7 CD34
8 CSF
9 Graft vs Host Disease
10 Granulocyte Colony-Stimulating Factor
11 Hematopoietic Stem Cell Mobilization
12 Homologous Transplantation
13 IFN-g
14 IL
15 T cell
16 T lymphocyte
17 Th1
18 Th2
19 Tissue Donor
20 United State Food and Drug Administration
21 adequate number
22 age
23 agent
24 allograft
25 binding
26 biological impact
27 blood circulation
28 bone marrow
29 cell
30 cellular content
31 cellular population
32 cellular subset
33 chemokine receptor
34 cluster
35 collection
36 combining
37 dose
38 drug
39 ease
40 effective agent
41 effective strategy
42 engraftment
43 fold increase
44 graft host disease
45 graft-versus-leukemia
46 growth factor
47 healthy donor
48 healthy volunteer
49 hematopoetic stem cell
50 hematopoietic stem cell
51 immune cell
52 immunological property
53 immunological study
54 individual
55 interferon
56 interleukin
57 large number
58 large volume
59 leukemia
60 lymphoma
61 mcg/kg
62 mobilization
63 multiple myeloma
64 negative impact
65 parallel study
66 patient
67 peripheral blood
68 peripheral blood progenitor cell
69 peripheral blood stem cell
70 plerixafor
71 polarization
72 population
73 primary endpoint
74 primary objective
75 procure
76 product
77 progenitor
78 ratio
79 recent data
80 regimen
81 safety profile
82 secondary endpoint
83 single dose
84 stem cell
85 stromal cell
86 sufficient quantity
87 transplantation
88 schema:name Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers
89 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00082329
90 schema:sdDatePublished 2019-03-07T15:21
91 schema:sdLicense https://scigraph.springernature.com/explorer/license/
92 schema:sdPublisher N38780a6f08314077871906aa69dd31d2
93 schema:sponsor https://www.grid.ac/institutes/grid.279885.9
94 https://www.grid.ac/institutes/grid.410305.3
95 schema:startDate 2004-05-01T00:00:00Z
96 schema:subjectOf sg:pub.10.1038/sj.bmt.1701522
97 sg:pub.10.1038/sj.bmt.1702464
98 https://app.dimensions.ai/details/publication/pub.1082852193
99 schema:url https://clinicaltrials.gov/show/NCT00082329
100 sgo:license sg:explorer/license/
101 sgo:sdDataset clinical_trials
102 rdf:type schema:MedicalStudy
103 N38780a6f08314077871906aa69dd31d2 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
106 rdf:type schema:DefinedTerm
107 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
108 rdf:type schema:DefinedTerm
109 sg:pub.10.1038/sj.bmt.1701522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046074771
110 https://doi.org/10.1038/sj.bmt.1701522
111 rdf:type schema:CreativeWork
112 sg:pub.10.1038/sj.bmt.1702464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035763692
113 https://doi.org/10.1038/sj.bmt.1702464
114 rdf:type schema:CreativeWork
115 https://app.dimensions.ai/details/publication/pub.1082852193 schema:CreativeWork
116 https://www.grid.ac/institutes/grid.279885.9 schema:Organization
117 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...